Curia Supports Replicate Bioscience’s Phase 1 Clinical Trial of Novel Next-Generation RNA Vaccine

Supply of drug substance manufactured under cGMP supports first-in-human clinical study for RBI-4000 novel self-replicating RNA (srRNA)

ALBANY, N.Y., Sept. 13, 2023 (GLOBE NEWSWIRE) — Curia, a leading contract research, development and manufacturing organization, today announced that its partner, Replicate Bioscience, has received IND clearance from the FDA and has dosed the first participant with RBI-4000, a self-replicating (srRNA) rabies vaccine, in a Phase 1 clinical study utilizing clinical material developed as part of the collaboration with Curia.

Curia conducted process development, scale-up and cGMP manufacture of srRNA RBI-4000 drug substance. At approximately 10,000 bases, this srRNA is significantly larger than a conventional linear mRNA and has been historically difficult to manufacture at the scales required for clinical development. Curia’s analytical method development and qualification of the assays were also critical to the release of this srRNA molecule.

“Curia is proud to be a pioneer in manufacturing this new class of srRNA technology by delivering RBI-4000 srRNA drug substance to our partner Replicate in support of their Phase 1 clinical trial,” said Christopher Conway, President, Research & Development, Curia. “We are dedicated to providing advantaged solutions from development to cGMP manufacture for our customers in the mRNA field.”

This new class of srRNA vaccine offers a number of potential improvements to existing mRNA vaccines, including lower dosage requirements and improved tolerability. The advancement also opens the door for further RNA innovation for use in vaccines and therapeutics with fewer constraints on molecule size.

“Our collaboration with Curia helped us manufacture a new class of self-replicating RNAs which have the potential to deliver improved bioactivity, tolerability and efficacy profiles as compared to other RNA technologies,” said Nathaniel Wang, Ph.D., founder and CEO of Replicate. “Curia scaled up a process for longer RNAs that enabled large-scale production at yields, purity and potency to support Replicate’s Phase 1 clinical trial.”

Curia is committed to being a partner of choice from discovery and development through manufacture and commercialization, providing a full suite of services to support small and large molecule, drug substance, drug product aseptic fill-finish and laboratory testing at every phase of the drug development life cycle.

About Curia
Curia, formerly AMRI, is a leading contract research, development, and manufacturing organization providing products and services from R&D through commercial manufacturing to pharmaceutical and biopharmaceutical customers. Curia’s nearly 4,000 employees at 29 locations across the U.S., Europe, and Asia help its customers advance from curiosity to cure. Learn more at CuriaGlobal.com.

Curia Contact Information:
Viana Bhagan
+1 518 512 2111
corporatecommunications@CuriaGlobal.com

GlobeNewswire Distribution ID 8920285

Annual Investment Meeting announces new identity as AIM Congress, gears up for 13th edition in Abu Dhabi, May 2024

ABU DHABI, United Arab Emirates, Sept. 13, 2023 (GLOBE NEWSWIRE) — Under its new identity as “AIM Congress,” the Organizing Committee of the World’s Leading Investment Platform will once again gather together regional and international leaders, thinkers, and innovators at the 13th edition of the event taking place from 7 to 9 May 2024 at the Abu Dhabi National Exhibition Centre.

To be anchored on the theme “Adapting to a Shifting Investment Landscape: Harnessing New Potential for Global Economic Development,” AIM Congress 2024 is supported by the Ministry of Industry and Advanced Technology and the Abu Dhabi Department of Economic Development (ADDED) as lead partner.

To be hosted again in the UAE’s vibrant capital, AIM Congress 2024 plans to surpass the success achieved by its last year’s edition which attracted 10,313 participants and 693 speakers from 175 countries.

His Excellency Dr. Thani bin Ahmed Al Zeyoudi, UAE Minister of State for Foreign Trade, expressed his enthusiasm for AIM Congress 2024, stating that, “For more than a decade, AIM Congress has been steadfast in its commitment to promote global economic cooperation and harness the potential of countries especially emerging markets. Amid the backdrop of the shifting global investment scene, it is all-important for countries to adapt and explore new avenues for growth. For its 2024 edition, AIM Congress will continue to be the leading venue where the world’s key economic stakeholders congregate to facilitate dialogue and pave the way for impactful investments that propel a brighter, better future for each and everyone.”

His Excellency Ahmed Jasim Al Zaabi, Chairman of ADDED, said: “Building on the remarkable success of AIM’s previous edition, we are raising the bar to meet the expectations of the global investment community. As the Capital of Capital, Abu Dhabi is leading global conversations on investments outlook and dynamics in an era characterised by mega shifts. Our approach to inward and outward investments is guided by our unwavering commitment to place human development, sustainability, and advanced technology at the core of socio-economic plans at local and international levels, support of ESG agendas, and enhance synergies through international cooperation to improve life for all.”

For his part, Dawood Al Shezawi, President of AIM Global Foundation, commented: “In the face of the various challenges confronting our world today, coupled with the continued decline in global economic growth, emerges the announcement of AIM’s new identity as AIM Congress, which positions itself as a premier venue for investment, providing the optimal platform for esteemed leaders and decision-makers around the world to collectively address our most pressing issues, reshape the global trade and investment landscape, and ultimately foster positive, enduring social and economic impacts in diverse regions worldwide.”

AIM Congress is built upon a foundation of its five key pillars – FDI, FPI, Startups, SMEs, and Future Cities – that underpin the event’s objectives and provide a framework for its activities.

For more details
Shreya Verma – +971 521133926
shreya.verma@aimcongress.com

GlobeNewswire Distribution ID 1000839289

THE PRAX GROUP ANNOUNCES SUCCESSFUL CLOSING OF A US$300 MILLION PRIVATE CREDIT FACILITY

London, Sept. 12, 2023 (GLOBE NEWSWIRE) — The Prax Group (“Prax”) – a British multinational, independent global energy conglomerate dealing in crude oil, petroleum products and biofuels, with a complete integration across the oil value chain, from upstream to midstream and downstream – has announced the successful closing of a new privately placed c.US$300 million (equivalent) Term Loan Facility (the “Facility”).  The Facility achieved a substantial oversubscription and was upsized from an original US$250 million, with four institutions participating in the transaction, including three new lenders.

The Private Credit team at HSBC Bank plc (“HSBC”) acted as Sole Mandated Lead Arranger of the transaction. Funds managed by institutional investors including Chimera Abu Dhabi (“Chimera”) and Orchard Global Asset Management (“Orchard Global”) acted as lenders alongside HSBC.

Ben Lahnstein, Group Chief Financial Officer, Prax, said: “The success of the transaction highlights the confidence our lending groups have in Prax and the depth of our banking and investor relationships. This latest funding has diversified our funding sources and strengthened our balance sheet.  It provides us with a solid financial platform from which to execute future M&A activities, and deliver sustainable, profitable growth.”

The new Facility will be used to refinance the maturing five-year term loan tranche from 2018, as well as for strategic acquisitions.

| ENDS |

Notes to Editors

About The Prax Group: Headquartered in the UK, the Prax Group is a British multinational, independent exploration and production, refining, storage, distribution and sales conglomerate dealing in petroleum products and bio-fuels. The Prax Group has a complete integration across the whole oil value chain, from upstream to midstream and downstream, with offices in London, Houston and Singapore. The Group strives to limit its carbon footprint and to embrace the advent of transitional fuels.

www.prax.com

Corporate Headquarters:
Prax Group
York House
45 Seymour Street
London W1H 7JT
United Kingdom
Email: press@prax.com

Attachments

Prax Group
press@prax.com

GlobeNewswire Distribution ID 8921162

Nyxoah to Participate in the Cantor Fitzgerald Global Healthcare Conference

Nyxoah to Participate in the Cantor Fitzgerald Global Healthcare Conference

Mont-Saint-Guibert, Belgium – September 12, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Cantor Fitzgerald Global Healthcare Conference, which takes place September 26 – 28, 2023 in New York, New York.

Olivier Taelman, Nyxoah’s Chief Executive Officer, will deliver a corporate update on Wednesday, September 27, 2023, at 9:45am EST. A webcast of the presentation will be available on the Events section of Nyxoah’s Investor Relations website. The Company will also be available for 1×1 meetings with institutional investors attending the event.

Nyxoah’s Investor Presentation can be accessed on the Shareholder Information section of the Company’s Investor Relations page.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and U.S. commercialization approval.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Contact:
Nyxoah
David DeMartino, Chief Strategy Officer
david.demartino@nyxoah.com
+1 310 310 1313

Attachment

GlobeNewswire Distribution ID 1000839179

‫ملتقى الاستثمار السنوي يعلن عن هويته الجديدة تحت مسمى قمة (AIM) للاستثمار

أبو ظبي (الإمارات العربية المتحدة) 12 سبتمبر 2023: أعلنت اللجنة المنظمة لقمة AIM للاستثمار “ملتقى الاستثمار السنوي” أحد أكبر التجمعات الاستثمارية حول العالم، عن انطلاق فعاليات الدورة الثالثة عشرة تحت شعار “التكيف مع تحول المشهد الاستثماري: تسخير إمكانات جديدة لتطوير التنمية الاقتصادية عالميًا “، بحلتها الجديدة وذلك خلال الفترة من 7 إلى 9 مايو المقبل، في مركز أبوظبي الوطني للمعارض.

وتستضيف العاصمة أبوظبي للسنة الثانية على التوالي فعاليات قمة (AIM) للاستثمار بدعم من وزارة الصناعة والتكنولوجيا المتقدمة، ودائرة التنمية الاقتصادية – أبوظبي (الشريك الرئيسي)، بعد النجاح الباهر الذي حققته الدورة السابقة، باستقطاب 10313 مشاركاً من 175 دولة حول العالم، وشهدت 281 جلسة ضمت 693 متحدثاً.

 وتسعى القمة من خلال تنظيم باقة من الفعاليات والأنشطة المتنوعة، إلى توفير منصة مثالية تجمع نخبة القادة، والمسؤولين الحكوميين، وصنّاع القرار والسياسات، ورجال الأعمال، وكبار المستثمرين الإقليميين والدوليين، وكبريات الشركات والمنظمات العالمية، على مدار ثلاثة أيام لتسليط الضوء على المستجدات في المشهد الاستثماري العالمي، والخروج بحلول مبتكرة لمواجهة التحديات والمتغيرات الحالية والمستقبلية، وصولًا إلى اقتصاد عالمي مزدهر ومستدام.

وقال معالي الدكتور ثاني بن أحمد الزيودي، وزير دولة للتجارة الخارجية: “نجحت قمة (AIM) للاستثمار على مدار أكثر من عقد في تقديم منصة رائدة لصناع القرار وقادة الأعمال والمستثمرين والمسؤولين الحكوميين لمناقشة واستكشاف سبل جديدة لتعزيز التعاون الاقتصادي والاستثماري عالمياً.”

وأضاف معاليه إن استضافة مثل هذه الفعاليات الدولية المهمة تعزز المكانة الاستراتيجية لدولة الإمارات على خريطة الاستثمار العالمية بوصفها وجهة استثمارية مفضلة للاستثمارات الدولية الباحثة عن فرص للنمو والتوسع والازدهار، بالإضافة إلى كونها واحدة من أكبر الدول المستثمرة حول العالم، كما تتماشى مع توجهات دولة الإمارات الاستثمارية الرامية إلى المساهمة في تخطي التحديات الراهنة التي تواجه الاقتصاد العالمي، وتحقيق التنمية والازدهار والاستدامة في الدول المستقبلة للاستثمارات الإماراتية.

من جانبه، قال معالي أحمد جاسم الزعابي، رئيس دائرة التنمية الاقتصادية – أبوظبي: “انطلاقًا من النجاح الملحوظ الذي حققته الدورة السابقة من قمة (AIM) للاستثمار، فإننا نعمل لتلبية مستوى عال من توقعات مجتمع الاستثمار العالمي. باعتبارها عاصمة رؤوس الأموال، تقود أبوظبي المحادثات العالمية حول توقعات وديناميكيات الاستثمار في عصر يتسم بالتحولات الضخمة. نسعى لتحفيز واستقطاب وتوجيه الاستثمارات الداخلية والخارجية من خلال نهج يرتكز على جعل التنمية البشرية ومعايير الاستدامة وتوظيف التكنولوجيا المتقدمة المحور والمحرك الرئيسي لخطط التنمية الاجتماعية والاقتصادية على المستويين المحلي والدولي، فضلًا عن دعم جداول الأعمال البيئية والاجتماعية والحوكمة، وتعزيز التعاون والعمل الدولي المشترك لتحسين جودة الحياة للجميع.”

وقال داوود الشيزاوي رئيس مؤسسة (AIM) العالمية: “في ظل ما يشهده العالم من تحديات مختلفة مثل تغير المناخ، وتحديات سلاسل الإمداد العالمية، والأمن الغذائي، وتضخم الأسعار، وبالتزامن مع استمرار انخفاض النمو الاقتصادي العالمي، يأتي الإعلان عن الهوية الجديدة لقمة (AIM) للاستثمار لتوفير منصة مثالية لنخبة القادة وصناع القرار حول العالم لتبادل الخبرات والتجارب والآراء حول كيفية التصدي لتلك التحديات وإعادة تشكيل مشهد التجارة والاستثمار العالمي.

وتنظم القمة باقة من الفعاليات ضمن محوري الاستثمار والابتكار والتكنولوجيا، حول موضوعات مختلفة تشمل الزراعة، والطاقة، والتكنولوجيا، والصناعة، والسياحة، والشحن، والخدمات المالية، والصحة والتعليم، وذلك بالتعاون مع عدد من الهيئات الدولية مثل منظمة الصحة العالمية،  والسياحة العالمية، واليونيدو، والأونكتاد، ومنظمة التجارة العالمية، ومنظمة التعاون الاقتصادي والتنمية، والوكالة الدولية للطاقة المتجددة.

لأيةاستفساراتأوللرغبةفيالحصولعلىالمزيدمنالمعلوماتالرجاءعدمالترددبالاتصالفيأيوقت

شيرين المسلمي
M: +971 526998032
pr.media@aimcongress.com

GlobeNewswire Distribution ID 300893347

Institutional Investor Launches 2023 Developed Europe and 2023 Emerging EMEA Research Rankings

BofA Securities and BNP Paribas Exane share first place as top research provider in the Developed Europe survey

BofA Securities, HSBC and J.P. Morgan share top spot in Emerging EMEA

LONDON, Sept. 12, 2023 (GLOBE NEWSWIRE) —  Institutional Investor Research (II Research) surveys are the leading provider of market sentiment in the financial industry. Research budgets remain flat and asset managers are using fewer analysts, but demand for bespoke opinion means that close client relationships and “trusted source” status becomes more important than ever before. With MiFID regulations potentially being rolled back across Europe and UK, the focus on the provision of quality research advisory services may result in a more competitive environment and we may see an increase in research teams across the industry.

There were no changes to the industry and country sector categories this year. The 2023 Developed Europe Research results reflects the opinions of 5,462 portfolio managers and analysts (up from 4,692 in 2022) from 1,813 institutions (up from 1,696 in 2022). The total number of votes has also increased from last year, by 11%. Over 180 firms have submitted centralised or coordinated votes, underscoring the robust nature of the results as an accurate reflection of market sentiment.

Results Highlights

Developed Europe Research

The Leaders’ Board remains intensely competitive, with seven companies competing for the honour of being rated best research house. BofA Securities and BNP Paribas Exane were ranked in first place, both with 38 published positions. J.P. Morgan once again follows in third place taking 31 positions with UBS achieving fourth place with 30 ranked teams. Barclays built on the momentum they gathered in 2022, gaining three published positions and rising to 5th overall; Morgan Stanley places sixth. The largest gain on the Leader’s Board came from Jefferies in seventh, which gained 10 positions from 2022. Citi, Bernstein and Kepler Cheuvreux take the final three places in the Developed Europe Top 10, displacing Credit Suisse that shared joint 11th place with Societe Generale.

BNP Paribas Exane once again claims first place in the analyst-ranked tables with 44 positions, followed by BofA Securities (41), J.P. Morgan (35 positions) and Barclays (31), which climbed two places.

Emerging EMEA Research

HSBC and J.P. Morgan were joined by BofA Securities as joint first place in the Emerging EMEA Leaders’ Table all with 17 published positions. Morgan Stanley took fourth place with 8 positions. Citi and UBS shared fifth.

In the commission-weighted analyst tables, the top three positions were unchanged; HSBC came first with 33 published positions, followed by J.P. Morgan with 22 positions and BofA Securities with 18. Morgan Stanley pushed up seven places to 15 to take fourth and UBS came fifth place with 13 positions to complete the leading winners. Vote participation up 14% this year with 934 voters from 286 companies.

David Enticknap, Head of II Research said “With MiFID regulations potentially being rolled back across Europe and UK, the focus on the provision of quality research advisory services may result in a more competitive environment, and we may see an increase in research teams across the industry. The Institutional Investor rankings represent the gold standard in assessment of quality in equity research, recognised globally for the integrity of the process and depth of coverage.”

The results can be found here: https://www.institutionalinvestor.com/research

For more information, or a demo on how to interrogate the data, contact Augusta McKie, Sales Director Research (EMEA), augusta.mckie@iiresearch.com

To share your position on your website content, advertisements, communications and marketing collateral, please contact marketing@iiresearch.com.

Media contact

David Bowen, Director of Marketing, Institutional Investor Research david.bowen@iiresearch.com

About Institutional Investor Research

For over 50 years, Institutional Investor has been conducting independent research surveys with global investment professionals who evaluate and determine the best performing sell side service providers, asset managers and CEOs, CFOs, IROs and IR Programs across Europe, Emerging EMEA, Asia Pacific, North America and Latin America. The research data independently captures evaluations of companies, investment professionals and executives from investment managers, banks, research providers and corporate issuers, to deliver detailed peer-to-peer comparative analyses every year; the feedback helps inform strategic decision making and improve resource and process management.

Follow Institutional Investor Research here https://www.linkedin.com/showcase/11222447

GlobeNewswire Distribution ID 8920402

Institutional Investor Launches 2023 Developed Europe & Emerging EMEA Executive Team Rankings

36 companies (Core, Large Cap & Small-Mid Cap) came first in at least five voting areas in their sectors in Developed Europe and 16 companies for Emerging EMEA

LONDON, Sept. 12, 2023 (GLOBE NEWSWIRE) — Institutional Investor Research (II Research) surveys are the leading provider of independent performance validation and market sentiment across 8 global capital markets. Executive Team surveys are an independent platform for investment and sell-side professionals to evaluate credibility, communication, financial stewardship and capital allocation of corporate leadership, the quality of IR across multiple activities and the effectiveness of the Board of Directors. The results from the survey, an in-depth capability and benchmark analysis, capture the feeling and trust levels of stakeholders in their equity assets.

This year saw 2,733 CEOs, CFOs, and IROs from 1,266 nominated companies receiving votes in the survey. Combined voters saw 1,872 voters from 851 voting companies. The number of votes increased by over 20% since 2022 for the Developed Europe survey and 46% for the Emerging EMEA survey.

2023 Emerging EMEA Executive Team — Core results

281 companies and 503 individuals were nominated across 11 sectors.

Eight companies clinched a clean sweep first place in the combined rankings in five voting areas for Best CEO, Best CFO, Best Investor Relations Professional, Best IR Company, Best Analyst/Investor Event, Best ESG Metrics, and Best Company Board in their respective sectors:

Al Rajhi Bank (Saudi Arabia, Financials), Coca-Cola Icecek (Turkey, Consumer), Haci Omer Sabanci Holding (Turkey, Industrials), Hellenic Telecommunications Organization (Greece, Technology, Media & Telecommunications), Lamda Development (Greece, Construction & Real Estate), MLP Saglik Hizmetleri (Turkey, Health Care & Pharmaceuticals), Mytilineos Holdings (Greece, Metals & Mining) and Petkim Petrokimya Holding (Turkey, Chemicals).

2023 Emerging EMEA Executive Team — Large Cap results

95 companies and 197 individuals were nominated across 11 sectors.

Six companies clinched a clean sweep first place in the combined rankings five of the seven aforementioned voting areas:

Al Rajhi Bank (Saudi Arabia, Financials), Emaar Properties (United Arab Emirates, Construction & Real Estate), Hellenic Telecommunications Organization (Greece, Technology, Media & Telecommunications), Koc Holding (Turkey, Industrials), Opap (Greece, Consumer) and Turk Hava Yollari (Turkey, Transportation).

2023 Emerging EMEA Executive Team — Small & Midcap results

186 companies and 306 individuals were nominated across 11 sectors.

Ten companies obtained a clean sweep first place in the combined rankings in five of the seven aforementioned voting areas:

Aegean Airlines (Greece, Transportation), Coca-Cola Icecek (Turkey, Consumer), Haci Omer Sabanci Holding (Turkey, Industrials), Lamda Development (Greece, Construction & Real Estate), MLP Saglik Hizmetleri (Turkey, Health Care & Pharmaceuticals), Motor Oil (Hellas) Corinth Refineries (Greece, Oil & Gas), Mytilineos Holdings (Greece, Metals & Mining), Petkim Petrokimya Holding (Turkey, Chemicals), Piraeus Financial Holdings (Greece, Financials) and Turk Telekomunikasyon (Turkey, Technology Media & Telecommunications).

Amani Korayeim, Director for Europe and Emerging EMEA, says “The Institutional Investor rankings are recognised as an industry benchmark by its stakeholders and determine compensation packages and KPIs for IR teams that are empowered and valued by their leadership teams. Investor Relations is critical in shareholder value creation. In fact, good IR, often recognised through the Institutional Investor’s rankings, can deliver a competitive advantage, and help companies trade at a premium. Conversely, poor IR can lead to the company being traded at a discount, create greater volatility and higher cost of capital. The highest ranked companies in our surveys tend to measure and monitor the effectiveness of their IR activities very closely. These are the teams that take a strategic and deliberate approach to their market engagement, use underlying research data and perception intelligence to continually optimise their IR interaction to close the gap between their competition and lock in prospect targets through a more personalised and targeted outreach. Congratulations to all the top ranked companies this year, we are particularly excited about the new names and regions that are represented in what the market defines as Best in Class IR.”

For the full list of published winners, please visit www.institutionalinvestor.com/research.

Awards & Licences

Institutional Investor owns the copyright to all survey and awards logos. To acquire access to the Institutional Investor award or survey logo for use in client pitch books, annual reports, websites, email signatures, local advertising, social media etc., please contact marketing@iiresearch.com

Ranking Analysis & Perception Intelligence

To request further information on how you can access the underlying survey research to identify strength and opportunities in IR through a multi-dimensional comparative peer analysis, please contact amani.korayeim@iiresearch.com

Media contact

David Bowen, Director of Marketing, Institutional Investor Research david.bowen@iiresearch.com

About Institutional Investor Research

For over 50 years, Institutional Investor has been conducting independent research surveys with global investment professionals who evaluate and determine the best performing sell side service providers, asset managers and CEOs, CFOs, IROs and IR Programs across Europe, Emerging EMEA, Asia Pacific, North America and Latin America. The research data independently captures evaluations of companies, investment professionals and executives from investment managers, banks, research providers and corporate issuers, to deliver detailed peer-to-peer comparative analyses every year; the feedback helps inform strategic decision making and improve resource and process management.

Follow Institutional Investor Research here https://www.linkedin.com/showcase/11222447

GlobeNewswire Distribution ID 8920411